A pharmacological study of M1151C2

A pharmacological study of M1151C2 to assess effect on local safety

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031210012

Enrollment

Registered

2021-04-06

Start date

2021-04-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis

Interventions

apply appropriate amount of Tacrolimus ointment 0.1% to the affected areas of the skin once daily

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Confirmed diagnosis of atopic dermatitis

Exclusion criteria

Exclusion criteria: Patients with a history of, or currently with any of the following diseases: 1) malignact tumor 2) Serious allergy (shock, anaphylactoid symptoms) 3) Allergy to tacrolimus 4) Cutaneous hypersensitivity to topical drugs (e.g., allergic contact dermatitis) Patients with any of the following diseases: 1) Diseases considered inappropriate for study participation, such as serious cardiac, hepatic, renal, pulmonary, or hematologic diseases 2) Severe renal dysfunction, severe hyperkalemia or symptoms caused by them 3) ulcer or erosion clearly forming a plaque at the application site of the investigational drug 4) Diseases with ichthyosis-like erythroderma (Netherton syndrome, etc.) 5) Skin infections at the application site of the investigational

Design outcomes

Primary

Measure	Time frame
usability of the investigational	—

Contacts

Public ContactInfomation Clinical

Maruho Co.,Ltd. Kyoto R&D Center

ctinfo@mii.maruho.co.jp+81-75-325-3279

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026